Research Article
Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide
Table 2
Treatment characteristics and clinical outcomes.
| | Characteristic | Whole cohort (n = 153) | CRP/Alb <0.75 (n = 92) | CRP/Alb ≥0.75 (n = 61) | value |
| | Radiotherapy technique, n (%) | | | | | | 3D-CRT (60 Gy) | 106 (69.3) | 63 (68.5) | 43 (70.5) | 0.81 | | SIB-IMRT (70 Gy) | 47 (30.7) | 29 (31.5) | 18 (29.5) | | Adjuvant TMZ cycles, n (%) | | | | | | 1–5 | 48 (31.4) | 31 (33.7) | 17 (27.9) | 0.63 | | 6–12 | 105 (68.6) | 61 (66.3) | 44 (72.1) | | Brain failure, n (%) | | | | | | None | 9 (5.7) | 7 (7.6) | 2 (3.3) | 0.42 | | Infield | 120 (78.8) | 75 (81.5) | 45 (73.7) | | Marginal | 14 (9.9) | 6 (6.5) | 8 (13.1) | | Distant | 4 (2.8) | 2 (2.2) | 2 (3.3) | | Infield and distant | 4 (1.4) | 2 (2.2) | 2 (3.3) | | Marginal and distant | 2 (1.4) | 0 (0) | 2 (3.3) | | Salvage treatment, n (%) | | | | | | None | 58 (38.0) | 37 (40.2) | 21 (34.4) | 0.50 | | Ctx | 23 (15.0) | 14 (15.3) | 9 (14.8) | | RO | 12 (7.8) | 6 6.5) | 6 (9.8) | | SRS/SRT | 13 (8.6) | 6 (6.5) | 7 (11.5) | | RO + SRS/SRT | 12 (7.8) | 7 (7.6) | 5 (8.2) | | RO + Ctx | 15 (9.8) | 10 (10.9) | 5 (8.2) | | RO + SRS + Ctx | 12 (7.8) | 7 (7.6) | 5 (82) | | Unknown | 8 (5.2) | 5 (5.4) | 3 (4.9) | | OS | | | | | | Median, mo (95% CI) | 16.2 (12.7–19.7) | 22.5 (20.1–24.9) | 15.7 (13.5–17.9) | <0.001 | | 2 years, % | 25.4 | 41.7 | 16.2 | | 5 years, % | 9.5 | 20.0 | 0 |
|
|
CRP/Alb, CRP to albumin ratio; 3D-CRT, 3-dimensional conformal radiotherapy; SIB-IMRT, simultaneous integrated boost intensity-modulated radiotherapy; TMZ, temozolomide; RO, reoperation; SRS/SRT, stereotactic radiosurgery/stereotactic radiotherapy; Ctx, chemotherapy; OS, overall survival; CI, confidence interval.
|
